Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor

Oncogene

Volumn 32, Issue 1, 2013, Pages 27-38

  Yoshikawa, S ^a   Kukimoto Niino, M ^a   Parker, L ^a   Handa, N ^a   Terada, T ^a   Fujimoto, T ^a   Terazawa, Y ^a   Wakiyama, M ^a   Sato, M ^b   Sano, S ^b   Kobayashi, T ^b   Tanaka, T ^b   Chen, L ^c   Liu, Z J ^c,g   Wang, B C ^c   Shirouzu, M ^a   Kawa, S ^d,h   Semba, K ^e   Yamamoto, T ^d,f   Yokoyama, S ^a,d  

^a RIKEN YOKOHAMA INSTITUTE   (Japan)

^b JAPAN AEROSPACE EXPLORATION AGENCY   (Japan)

^c University of Georgia ^*  (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e WASEDA UNIVERSITY   (Japan)

^f OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY   (Japan)

^g INSTITUTE OF BIOPHYSICS   (China)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

drug resistance; EGFR; gefitinib; NSCLC; T790M; tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ARTICLE; BINDING AFFINITY; CANCER RESISTANCE; CHEMICAL ANALYSIS; DRUG POTENCY; DRUG SENSITIVITY; GENE MUTATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN CONFORMATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

PYRONIA TITHONUS;

EID: 84871998932     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.21     Document Type: Article

References (48)

1. Arteaga CL. (2002). Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29: 3-9.
2. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. (2008). Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 15: 1109-1118.
3. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW et al. (1998). Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54: 905-921.
4. Carmi C, Cavazzoni A, Vezzosi S, Bordi F, Vacondio F, Silva C et al. (2010). Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion. J Med Chem 53: 2038-2050.
5. Cha MY, Lee KO, Kim JW, Lee CG, Song JY, Kim YH et al. (2009). Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer. J Med Chem 52: 6880-6888.
6. Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J et al. (2011). Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer e-pub ahead of print 5 July 2011; doi: 10.1002/ijc.26276.
7. Collaborative Computational Project No.4 (1994). The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760-763.
8. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X et al. (2007). MolProbity: All-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35: W375-W383.
9. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T et al. (2007). A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 67: 6253-6262.
10. DeLano WL. (2005). PyMOL v.0.98. DeLano Scientific: South San Francisco, C.A.
11. Dixit A, Yi L, Gowthaman R, Torkamani A, Schork NJ, Verkhivker GM. (2009). Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS One 4: E7485.
12. Emsley P, Cowtan K. (2004). Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
13. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T et al. (2007). PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67: 11924-11932.
14. Garcia-Ruiz JM, Morena A. (1994). Investigations on protein crystal growth by the gel acupuncture method. Acta Crystallogr D Biol Crystallogr 50: 484-490.
15. Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT et al. (2008). Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res 68: 571-579.
16. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M et al. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: E313.
17. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, Griffin JD. (2005). Epidermal growth factor-independent transformation of Ba/ F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65: 8968-8974.
18. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47(Part 2): 110-119.
19. Kabsch W. (1976). A solution for the best rotation to relate two sets of vectors. Acta Crystallogr A 32: 922-923.
20. Kabsch W. (1993). Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 26: 795-800.
21. Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K et al. (2012). The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer 75: 161-166.
22. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. (2005). EGFR mutation and resistance of nonsmall- cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
23. Kornev AP, Haste NM, Taylor SS, Eyck LF. (2006). Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 103: 17783-17788.
24. Leslie AGW. (1992). Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography 26: 22-23.
25. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al. (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-4711.
26. Liu Y, Shah K, Yang F, Witucki L, Shokat KM. (1998). A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorg Med Chem 6: 1219-1226.
27. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
28. Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N et al. (2005). Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97: 1185-1194.
29. Murshudov GN, Vagin AA, Dodson EJ. (1997). Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255.
30. Otwinowski Z, Minor W. (1997). Processing of X-ray diffraction data collected in oscillation mode. Methods in Enzymol 276: 307-326.
31. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
32. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. (2004). EGF receptor gene mutations are common in lung cancers from 00never smokers00 and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311.
33. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: E73.
34. Read RJ. (2001). Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr 57: 1373-1382.
35. Shigematsu H, Gazdar AF. (2006). Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262.
36. Stamos J, Sliwkowski MX, Eigenbrot C. (2002). Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277: 46265-46272.
37. Suzuki T, J KT, Ajima R, Nakamura T, Yoshida Y, Yamamoto T. (2002). Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev 16: 1356-1370.
38. Taube E, Jokinen E, Koivunen P, Koivunen JP. (2011). A novel treatment strategy for EGFR mutant NSCLC with T790Mmediated acquired resistance. Int J Cancer e-pub ahead of print 27 September 2011; doi: 10.1002/ijc.26461.
39. Vagin A, Teplyakov A. (1997). MOLREP: An automated program for molecular replacement. J Appl Cryst 30: 1022-1025.
40. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ et al. (2002). ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754.
41. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH et al. (2004). A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659.
42. Wu CH, Coumar MS, Chu CY, Lin WH, Chen YR, Chen CT et al. (2010). Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: The role of side chain chirality and Michael acceptor group for maximal potency. J Med Chem 53: 7316-7326.
43. Yao M, Zhou Y, Tanaka I. (2006). LAFIRE: software for automating the refinement process of protein-structure analysis. Acta Crystallogr D Biol Crystallogr 62: 189-196.
44. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M et al. (2007). Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227.
45. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK et al. (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105: 2070-2075.
46. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.
47. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M et al. (2009). Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462: 1070-1074.
48. Zhou W, Ercan D, Janne PA, Gray NS. (2011). Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorg Med Chem Lett 21: 638-643.